Olotu A

The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.Manock SR, Nsue VU, Olotu A, Mpina M, Nyakarungu E, Raso J, Mtoro A, Ondo Mangue ME, Ntutumu Pasialo BE, Nguema R, Riyahi P, Schindler T, Daubenberger C, Church LWP, Billingsley PF, Richie TL, Abdulla S, Hoffman SL
Trans R Soc Trop Med Hyg, (2022). 116:745-749

Malaria hospitalisation in East Africa: age, phenotype and transmission intensity.Kamau A, Paton RS, Akech S, Mpimbaza A, Khazenzi C, Ogero M, Mumo E, Alegana VA, Agweyu A, Mturi N, Mohammed S, Bigogo G, Audi A, Kapisi J, Sserwanga A, Namuganga JF, Kariuki S, Otieno NA, Nyawanda BO, Olotu A, Salim N, Athuman T, Abdulla S, Mohamed AF, Mtove G, Reyburn H, Gupta S, Lourenco J, Bejon P, Snow RW
BMC Med, (2022). 20:28

Providing Ancillary Care in Clinical Research: A Case of Diffuse Large B-Cell Lymphoma during a Malaria Vaccine Trial in Equatorial Guinea.Manock SR, Mtoro A, Urbano Nsue Ndong V, Olotu A, Chemba M, Sama Roca AE, Eburi E, Garcia GA, Cortes Falla C, Niemczura de Carvalho J, Contreras J, Saturno B, Riocalo JD, Nze Mba JL, Koka R, Lee ST, Menon H, Church LWP, Ayekaba MO, Billingsley PF, Abdulla S, Richie TL, Hoffman SL
Am J Trop Med Hyg, (2020). 104:695-699

The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical Research Platform to Malaria Elimination Planning in Central West Africa.Billingsley PF, Maas CD, Olotu A, Schwabe C, Garcia GA, Rivas MR, Hergott DEB, Daubenberger C, Saverino E, Chaouch A, Embon O, Chemba M, Nyakarungu E, Hamad A, Cortes C, Schindler T, Mpina M, Mtoro A, Sim BKL, Richie TL, McGhee K, Tanner M, Obiang Lima GM, Abdulla S, Hoffman SL, Ayekaba MO
Am J Trop Med Hyg, (2020). 103:947-954

Detection of malaria parasites in dried human blood spots using mid-infrared spectroscopy and logistic regression analysis.Mwanga EP, Minja EG, Mrimi E, Jimenez MG, Swai JK, Abbasi S, Ngowo HS, Siria DJ, Mapua S, Stica C, Maia MF, Olotu A, Sikulu-Lord MT, Baldini F, Ferguson HM, Wynne K, Selvaraj P, Babayan SA, Okumu FO
Malar J, (2019). 18:341

High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria.Offeddu V, Olotu A, Osier F, Marsh K, Matuschewski K, Thathy V
Front Immunol, (2017). 8:488

Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study.Gitaka J, Ogwang C, Ngari M, Akoo P, Olotu A, Kerubo C, Fegan G, Njuguna P, Nyakaya G, Otieno T, Mwambingu G, Awuondo K, Lowe B, Chilengi R, Berkley JA
PLoS One, (2017). 12:e0177382

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, Kaslow DC, Njuguna P, Marsh K, Bejon P
N Engl J Med, (2016). 374:2519-29

Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity.Rono J, Farnert A, Murungi L, Ojal J, Kamuyu G, Guleid F, Nyangweso G, Wambua J, Kitsao B, Olotu A, Marsh K, Osier FH
BMC Med, (2015). 13:114

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.Olotu A, Clement F, Jongert E, Vekemans J, Njuguna P, Ndungu FM, Marsh K, Leroux-Roels G, Bejon P
PLoS One, (2014). 9:e115126

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.White MT, Bejon P, Olotu A, Griffin JT, Bojang K, Lusingu J, Salim N, Abdulla S, Otsyula N, Agnandji ST, Lell B, Asante KP, Owusu-Agyei S, Mahama E, Agbenyega T, Ansong D, Sacarlal J, Aponte JJ, Ghani AC
BMC Med, (2014). 12:117

CD4+ T cell responses to the Plasmodium falciparum erythrocyte membrane protein 1 in children with mild malaria.Gitau EN, Tuju J, Karanja H, Stevenson L, Requena P, Kimani E, Olotu A, Kimani D, Marsh K, Bull P, Urban BC
J Immunol, (2014). 192:1753-61

Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, Bejon P
BMC Med, (2013). 11:184

The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection.White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC
PLoS One, (2013). 8:e61395

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, Njuguna P, Peshu N, Marsh K, Bejon P
N Engl J Med, (2013). 368:1111-20

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Bejon P, White MT, Olotu A, Bojang K, Lusingu JP, Salim N, Otsyula NN, Agnandji ST, Asante KP, Owusu-Agyei S, Abdulla S, Ghani AC
Lancet Infect Dis, (2013). 13:319-27

Feedback of research findings for vaccine trials: experiences from two malaria vaccine trials involving healthy children on the Kenyan Coast.Gikonyo C, Kamuya D, Mbete B, Njuguna P, Olotu A, Bejon P, Marsh V, Molyneux S
Dev World Bioeth, (2013). 13:48-56

Phenotypic and functional profiling of CD4 T cell compartment in distinct populations of healthy adults with different antigenic exposure.Roetynck S, Olotu A, Simam J, Marsh K, Stockinger B, Urban B, Langhorne J
PLoS One, (2013). 8:e55195

Approaching the community about screening children for a multicentre malaria vaccine trial.Lang TA, Gould J, von Seidlein L, Lusingu JP, Mshamu S, Ismael S, Liheluka E, Kamuya D, Mwachiro D, Olotu A, Njuguna P, Bejon P, Marsh V, Molyneux C
Int Health, (2012). 4:47-54

Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.Ibison F, Olotu A, Muema DM, Mwacharo J, Ohuma E, Kimani D, Marsh K, Bejon P, Ndungu FM
PLoS One, (2012). 7:e52939